InventHelp Inventor Develops Vehicle Locating Accessory (RKH-719)
"I wanted to create a convenient and highly visible vehicle accessory to help direct you straight towards your vehicle when ...
GitHub15d
Ninja-Coder-ui/Parking-Lot-Using-Arduino
This project implements an automated parking lot system using Arduino, featuring IR sensors, servo motors, and LED indicators. The system can detect vehicle presence and control parking barriers ...
WCCB16d
North Carolina lawmakers introduce bill targeting parking lots
Carter is a Catawba Riverkeeper – and he’s had enough of the sprawling parking lots littered across the Queen City and the Tar Heel State. House Bill 369 – the Parking Lot Reform & Modernization Act – ...
GitHub16d
parking-lot
This project introduces an innovative parking management system driven by the STM32F401VE microcontroller. Experience efficient, hassle-free parking with real-time monitoring and smart features.
pulmonologyadvisor18d
Novo Nordisk Provides Direct-to-Patient Delivery Option for Wegovy
For eligible patients, health care providers can send Wegovy prescriptions directly to NovoCare Pharmacy. Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide) through the ...
Finanznachrichten18d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
NBC DFW18d
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Business Insider18d
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
BioPharma Dive19d
Novo’s Wegovy successor disappoints in second large trial
Novo had an early lead on Lilly, with Wegovy reaching market before Lilly’s rival Zepbound and, at least so far, securing broader insurance coverage. But that early advantage may be dissipating.
The Australian Financial Review19d
Ozempic maker says its Australian market could be half the population
Danish pharmaceutical giant Novo Nordisk says about 13 million Australians ... are proven to help people lose weight, there is still a lot they do not know about the long-term effects of managing ...
How a Copenhagen housing project by a $23 billion Novo-backed firm is rethinking big-city challenges like loneliness and access to sunlight
If you want to address civilization and society's issues, then you have to do it with the city," Urban Partners' co-CEO Claus Mathisen said.